Stock markets are fixated on Fed policy, but two experts believe investors should forget the U.S. central bank for now.» Read More
NEW YORK, Sept 21- Shares in biotech stocks tumbled on Monday, after U.S. Democratic presidential candidate Hillary Clinton tweet against "price gouging" in specialty drug markets, citing a New York Times story and said a plan will be laid out on Tuesday to combat it. Gilead Sciences was off 2.5 percent at $105.76 and Biogen dropped 5.3 percent at $298.01.
Sept 21- Gilead Sciences Inc is edging closer to the approval of the first drug to fight all forms of hepatitis C as the drugmaker's experimental combination showed high rates of effectiveness in four late-stage studies. The combination reduces the need for genotyping and potential confusion about which regimen works in which patients, UBS AG's Matthew...
Sept 21- Gilead Sciences Inc said its experimental combination treatment was effective against all forms of hepatitis C infection, citing data from four late-stage studies. The U.S. Food and Drug Administration has granted the experimental combination "breakthrough therapy" status, expediting the development and review of the drug. The Foster City,...
CNBC Pro reached out to top Wall Street fund managers to find out where they are putting money to work ahead of a potential Fed rate increase.
Big tech names such as Facebook and Google have excelled this year, but one trader says the large cap tech ETF is a risky buy.
Sept 14- Raptor Pharmaceutical Corp said it did not plan to develop its liver drug after it failed to meet the main goal in a second mid-stage study, wiping out more than a third of the company's market value. The drug, RP103, was being tested in children with nonalcoholic steatohepatitis, which is characterized by fat buildup in the liver, along with inflammation...
Pros pick top small, mid and large cap stocks
The high-grade bond market is springing back to life as corporations race to issue new debt and get out in front of a possible Fed interest rate hike.
Sept 2- Gilead Sciences Inc said on Wednesday its experimental fixed-dose combination treatment for HIV proved as effective in a late-stage study as the company's widely used Truvada combo pill but with significantly less loss of bone mineral density and kidney function. Gilead shares were up 0.5 percent to $101.95 in morning trading on the Nasdaq, versus a...
Louis Navellier, whose "Squawk Box" model portfolio is up 19% this year, shares his views on how to ride out the volatility in the market.
Sept 1- Gilead Sciences Inc said on Wednesday its experimental fixed-dose combination treatment for HIV proved as effective in a late-stage study as the company's widely used Truvada combo pill but with significantly less loss of bone mineral density and kidney function. Gilead shares were up 1.6 percent to $102.88 in morning trading on the Nasdaq,...
Experienced investors use China-driven market selloffs to buy these quality companies.
Today's selloff is completely normal so panicking would be premature, says Ron Insana.
Nearly 400 members of the S&P 500 were "oversold" on a statistical basis at the end of last week and therefore should rebound this week.
The healthcare secular theme isn't new, but is still very much in force.
For this market to truly find a bottom, China needs to do more and the Fed needs to do less, says Ron Insana.
No matter what happens to the markets on Monday, there's going to be a lot of action in Apple either way.
Data from Axioma show that the most concentrated risk in the Nasdaq 100 is confined to the top six stocks.
Despite muted returns for the S&P 500 in 2015, analysts on Wall Street just love these stocks.
July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent, newly approved cholesterol drugs could "wreak financial havoc" among its clients. Express Scripts, which administers drug benefits for employers and health plans and also runs large mail-order pharmacies, has been challenging...